We are live on !
Find out more
Superstring Capital Management Portfolio holdings
AUM
$158M
Turnover
44.19%
1-Year Est. Return
418.32%
This Fund
S&P 500
This Quarter Est. Return
+56.37%
1 Year Est. Return
+418.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$102M
AUM Growth
+$17M
(+20%)
Cap. Flow
-$7.45M
Cap. Flow % of AUM
Cap. Flow %
-7.34%
Top 10 Holdings %
Top 10 Hldgs %
53.57%
Holding
52
New
16
Increased
7
Reduced
8
Closed
17
Avg Time Held
Equity + Options
0.5
years
Top 10 Avg Time Held
Equity + Options
0.5
years
Top 20 Avg Time Held
Equity + Options
0.3
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Immunovant
IMVT
|
+$5.53M |
| 2 |
Summit Therapeutics
SMMT
|
+$4.78M |
| 3 |
Cidara Therapeutics
CDTX
|
+$4.37M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$3.62M |
| 5 |
IQVIA
IQV
|
+$3.48M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cogent Biosciences
COGT
|
+$7.13M |
| 2 |
VRNA
Verona Pharma
VRNA
|
+$6.52M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$5.1M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$4.74M |
| 5 |
Travere Therapeutics
TVTX
|
+$4.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Zai Lab
ZLAB
$3.05B
| $6.8M | 6.7% |
200,628
+65,733
| +49% | +$2.26M |
2024 Q2
5 quarters
|
|
|
2
DELISTED
Cidara Therapeutics
CDTX
| $6.56M | 6.46% |
+68,463
| New | +$4.37M |
2025 Q3
0 quarters
|
|
3
DELISTED
Terns Pharmaceuticals
TERN
| $5.93M | 5.84% |
789,646
-497,035
| -39% | -$3.17M |
2024 Q2
5 quarters
|
|
4
DELISTED
89bio
ETNB
| $5.65M | 5.57% |
384,652
+172,275
| +81% | +$1.76M |
2023 Q4
7 quarters
|
|
|
5
Immunovant
IMVT
$7.11B
| $5.5M | 5.42% |
+341,348
| New | +$5.53M |
2025 Q3
0 quarters
|
|
6
Jazz Pharmaceuticals
JAZZ
$15.6B
| $5.39M | 5.31% |
40,893
-3,214
| -7% | -$385K |
2025 Q2
1 quarter
|
|
|
7
Cogent Biosciences
COGT
$4.98B
| $5.19M | 5.11% |
361,408
-601,543
| -62% | -$7.13M |
2024 Q4
3 quarters
|
|
8
Savara
SVRA
$1.04B
| $4.67M | 4.6% |
1,309,236
+193,857
| +17% | +$573K |
2023 Q4
7 quarters
|
|
9
BridgeBio Pharma
BBIO
$15.2B
| $4.6M | 4.54% |
88,658
-8,108
| -8% | -$395K |
2023 Q4
7 quarters
|
|
|
10
Summit Therapeutics
SMMT
$11.4B
| $4.08M | 4.01% |
+197,253
| New | +$4.78M |
2025 Q3
0 quarters
|
|
|
11
IQVIA
IQV
$43.8B
| $3.63M | 3.58% |
+19,114
| New | +$3.48M |
2025 Q3
0 quarters
|
|
12
Cabaletta Bio
CABA
$278M
| $3.61M | 3.56% |
1,544,525
+483,761
| +46% | +$830K |
2024 Q1
6 quarters
|
|
|
13
Regeneron Pharmaceuticals
REGN
$98.9B
| $3.6M | 3.55% |
+6,401
| New | +$3.62M |
2025 Q3
0 quarters
|
|
14
Bright Minds Biosciences
DRUG
$229M
| $3.27M | 3.22% |
+53,950
| New | +$2.09M |
2025 Q3
0 quarters
|
|
15
Nektar Therapeutics
NKTR
$1.28B
| $2.92M | 2.87% |
+51,270
| New | +$1.7M |
2025 Q3
0 quarters
|
|
16
Insmed
INSM
$26.6B
| $2.85M | 2.81% |
19,786
+5,215
| +36% | +$639K |
2025 Q2
1 quarter
|
|
17
Bicara Therapeutics
BCAX
$661M
| $2.78M | 2.74% |
175,902
-13,797
| -7% | -$154K |
2025 Q2
1 quarter
|
|
18
Avalo Therapeutics
AVTX
$453M
| $2.39M | 2.36% |
+188,080
| New | +$1.62M |
2025 Q3
0 quarters
|
|
19
Sanofi
SNY
$116B
| $2.38M | 2.34% |
+50,407
| New | +$2.43M |
2025 Q3
0 quarters
|
|
20
Zenas BioPharma
ZBIO
$1.91B
| $2.15M | 2.11% |
96,665
-14,940
| -13% | -$243K |
2024 Q3
4 quarters
|
|
21
uniQure
QURE
$1.69B
| $1.94M | 1.91% |
+33,175
| New | +$602K |
2025 Q3
0 quarters
|
|
22
Tectonic Therapeutic
TECX
$416M
| $1.87M | 1.84% |
119,286
+40,228
| +51% | +$830K |
2025 Q1
2 quarters
|
|
23
UroGen Pharma
URGN
$1.28B
| $1.75M | 1.73% |
87,912
| – | – |
2024 Q4
3 quarters
|
|
24
Protara Therapeutics
TARA
$157M
| $1.57M | 1.54% |
360,000
| – | – |
2024 Q4
3 quarters
|
|
25
Keros Therapeutics
KROS
$204M
| $1.5M | 1.48% |
+95,083
| New | +$1.4M |
2025 Q3
0 quarters
|
|
Similar funds
JAIC
Superstring Capital Management's Q3 2025 Portfolio in Review
As of Q3 2025, Superstring Capital Management held 52 positions worth $102M, up 20% from $84.5M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Superstring Capital Management withdrew a net $7.45M in Q3 2025, closing 17 positions and reducing 8 holdings. Its most notable exit was Verona Pharma, an estimated $6.52M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.
Against the trend, Superstring Capital Management opened a new position in Immunovant worth $5.5M.
- Superstring Capital Management's largest Q3 2025 buy was Immunovant: 341,348 shares worth $5.5M.
- Superstring Capital Management added most to Zai Lab in Q3 2025, an estimated $2.26M increase.
- Superstring Capital Management's biggest Q3 2025 reduction was Cogent Biosciences, cutting an estimated $7.13M.
- Superstring Capital Management fully exited Verona Pharma in Q3 2025, selling an estimated $6.52M.
- Superstring Capital Management's ten largest holdings make up 54% of its $102M portfolio in Q3 2025.
- Superstring Capital Management opened 16 new positions and closed 17 in Q3 2025.
- Superstring Capital Management's portfolio value rose 20% quarter-over-quarter to $102M.
Based on Superstring Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.